Bedeutung der Androgenrezeptor-Spleißvariante AR-V7 für Prognose und Therapie des fortgeschrittenen Prostatakarzinoms

P Thelen; H Taubert; S Duensing; G Kristiansen; A S Merseburger; M V Cronauer

doi:10.1055/s-0043-115426

Bedeutung der Androgenrezeptor-Spleißvariante AR-V7 für Prognose und Therapie des fortgeschrittenen Prostatakarzinoms

P Thelen, H Taubert, S Duensing, G Kristiansen, A S Merseburger, M V Cronauer

Abstract

A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. This review critically outlines recent advances in AR-V7 diagnostics and presents an overview of current AR-V7 targeted therapies.

Titel in Übersetzung	The impact of the androgen receptor splice variant AR-V7 on the prognosis and treatment of advanced prostate cancer
Originalsprache	Deutsch
Zeitschrift	Aktuelle Urologie
Jahrgang	51
Ausgabenummer	6
Seiten (von - bis)	582-592
Seitenumfang	11
ISSN	0001-7868
DOIs	https://doi.org/10.1055/s-0043-115426
Publikationsstatus	Veröffentlicht - 2020

Strategische Forschungsbereiche und Zentren

Zentren: Universitäres Cancer Center Schleswig-Holstein (UCCSH)

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

Zugriff auf Dokument

10.1055/s-0043-115426

Zitieren

@article{40db311d0e594aa9a0ca0121b55bb7b1,

title = "Bedeutung der Androgenrezeptor-Splei{\ss}variante AR-V7 f{\"u}r Prognose und Therapie des fortgeschrittenen Prostatakarzinoms",

abstract = "A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. This review critically outlines recent advances in AR-V7 diagnostics and presents an overview of current AR-V7 targeted therapies.",

author = "P Thelen and H Taubert and S Duensing and G Kristiansen and Merseburger, {A S} and Cronauer, {M V}",

year = "2020",

doi = "10.1055/s-0043-115426",

language = "Deutsch",

volume = "51",

pages = "582--592",

journal = "Aktuelle Urologie",

issn = "0001-7868",

number = "6",

}

TY - JOUR

T1 - Bedeutung der Androgenrezeptor-Spleißvariante AR-V7 für Prognose und Therapie des fortgeschrittenen Prostatakarzinoms

AU - Thelen, P

AU - Taubert, H

AU - Duensing, S

AU - Kristiansen, G

AU - Merseburger, A S

AU - Cronauer, M V

PY - 2020

Y1 - 2020

N2 - A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. This review critically outlines recent advances in AR-V7 diagnostics and presents an overview of current AR-V7 targeted therapies.

AB - A recently discovered mechanism enabling prostate cancer cells to escape the effects of endocrine therapies consists in the synthesis of C-terminally truncated, constitutively active androgen receptor (AR) splice variants (AR-V). Devoid of a functional C-terminal hormone/ligand binding domain, various AR-Vs are insensitive to therapies targeting the androgen/AR signalling axis. Preliminary studies suggest that AR-V7, the most common AR-V, is a promising predictive tumour marker and a relevant selection marker for the treatment of advanced prostate cancer. This review critically outlines recent advances in AR-V7 diagnostics and presents an overview of current AR-V7 targeted therapies.

U2 - 10.1055/s-0043-115426

DO - 10.1055/s-0043-115426

M3 - Übersichtsarbeiten

C2 - 29370587

SN - 0001-7868

VL - 51

SP - 582

EP - 592

JO - Aktuelle Urologie

JF - Aktuelle Urologie

IS - 6

ER -